X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5265) 5265
Book Review (843) 843
Publication (657) 657
Book Chapter (20) 20
Conference Proceeding (3) 3
Dissertation (2) 2
Book / eBook (1) 1
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4850) 4850
humans (4715) 4715
hematology (2513) 2513
fusion proteins, bcr-abl - genetics (2453) 2453
oncology (2099) 2099
chronic myelogenous leukemia (1767) 1767
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1688) 1688
male (1683) 1683
female (1542) 1542
chronic myeloid-leukemia (1508) 1508
imatinib mesylate (1376) 1376
adult (1270) 1270
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1251) 1251
middle aged (1235) 1235
animals (1229) 1229
leukemia (1187) 1187
chronic myeloid leukemia (1141) 1141
bcr-abl (1131) 1131
benzamides (1011) 1011
mice (999) 999
fusion proteins, bcr-abl - metabolism (976) 976
leukemia, myelogenous, chronic, bcr-abl positive - pathology (956) 956
hemic and lymphatic diseases (915) 915
imatinib (899) 899
aged (808) 808
cancer (807) 807
abridged index medicus (804) 804
mutation (772) 772
pyrimidines - therapeutic use (764) 764
antineoplastic agents - therapeutic use (732) 732
piperazines - therapeutic use (670) 670
genetic aspects (666) 666
research (661) 661
protein kinase inhibitors - therapeutic use (601) 601
acute lymphoblastic-leukemia (591) 591
fusion proteins, bcr-abl - antagonists & inhibitors (588) 588
philadelphia-chromosome (585) 585
cml (577) 577
pyrimidines - pharmacology (569) 569
oncogene proteins, fusion - genetics (547) 547
philadelphia chromosome (540) 540
adolescent (533) 533
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (533) 533
cell line, tumor (510) 510
apoptosis (508) 508
treatment outcome (505) 505
tyrosine kinase (499) 499
piperazines - pharmacology (486) 486
translocation, genetic (478) 478
cell biology (469) 469
antineoplastic agents - pharmacology (458) 458
reverse transcriptase polymerase chain reaction (451) 451
protein kinase inhibitors - pharmacology (436) 436
polymerase chain reaction (433) 433
precursor cell lymphoblastic leukemia-lymphoma - genetics (429) 429
prognosis (418) 418
analysis (410) 410
fusion protein (410) 410
care and treatment (408) 408
k562 cells (408) 408
tyrosine (408) 408
genetics & heredity (397) 397
gene expression (396) 396
in situ hybridization, fluorescence (391) 391
cells (389) 389
protein-tyrosine kinases - antagonists & inhibitors (387) 387
proteins (386) 386
therapy (382) 382
kinases (379) 379
biochemistry & molecular biology (368) 368
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (365) 365
dasatinib (361) 361
child (355) 355
expression (354) 354
stem cells (353) 353
apoptosis - drug effects (352) 352
phosphorylation (352) 352
gene (351) 351
signal transduction (350) 350
base sequence (346) 346
article (342) 342
health aspects (340) 340
drug resistance, neoplasm (336) 336
leukemia, myelogenous, chronic, bcr-abl positive - therapy (335) 335
rna, messenger - genetics (332) 332
bcr protein (329) 329
drug resistance, neoplasm - genetics (323) 323
molecular sequence data (320) 320
tumor cells, cultured (312) 312
neoplasms (309) 309
resistance (308) 308
young adult (307) 307
acute myeloid-leukemia (294) 294
hematology, oncology and palliative medicine (292) 292
minimal residual disease (288) 288
tyrosine kinase inhibitors (283) 283
abl protein (281) 281
aged, 80 and over (277) 277
genes (275) 275
remission induction (275) 275
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5159) 5159
Chinese (56) 56
Japanese (25) 25
German (9) 9
French (6) 6
Russian (5) 5
Spanish (5) 5
Czech (4) 4
Korean (3) 3
Hungarian (1) 1
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 01/2007, Volume 109, Issue 1, pp. 61 - 64
Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or alpha (PDGFRA) play an important role in the pathogenesis of... 
MESYLATE | TRANSCRIPTS | PROTEIN | STI571 | TRANSLOCATIONS | TYROSINE KINASE INHIBITOR | GROWTH-FACTOR RECEPTORS | FACTOR RECEPTOR-BETA | HEMATOLOGY | CHRONIC MYELOMONOCYTIC LEUKEMIA | CHRONIC MYELOID-LEUKEMIA | Translocation, Genetic | Follow-Up Studies | Receptor, Platelet-Derived Growth Factor beta - blood | Humans | Middle Aged | Drug Evaluation | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Receptor, Platelet-Derived Growth Factor beta - genetics | Myeloproliferative Disorders - genetics | RNA, Neoplasm - blood | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Myeloproliferative Disorders - blood | Fusion Proteins, bcr-abl - blood | Aged, 80 and over | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Adult | Female | Retrospective Studies | Child | Eosinophilia - etiology | Treatment Outcome | Myeloproliferative Disorders - drug therapy | Piperazines - therapeutic use | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Biomarkers, Tumor - blood | RNA, Messenger - blood | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - blood | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Aged | Oncogene Proteins, Fusion - blood | Benzamides | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2408 - 2417
The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON-ALPHA | CHRONIC-PHASE | ABL TYROSINE KINASE | COMPLETE CYTOGENETIC REMISSION | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | ALPHA PLUS CYTARABINE | Follow-Up Studies | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Fusion Proteins, bcr-abl - blood | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Interferon alpha | Clinical trials | Bone marrow | Transplants & implants | Pharmaceutical industry | Leukemia | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Journal Article
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 4, pp. 504 - 507
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2003, Volume 349, Issue 15, pp. 1423 - 1432
Journal Article
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 19, pp. 3818 - 3824
Journal Article
Cancer, ISSN 0008-543X, 07/2018, Volume 124, Issue 14, pp. 2956 - 2963
Clinical trials have demonstrated that patients with chronic‐phase chronic myeloid leukemia with deep and durable molecular responses can attempt to stop using... 
tyrosine kinase inhibitors | chronic myeloid leukemia | clinical practice | treatment discontinuation | recommendations | TREATMENT-FREE REMISSION | MANAGEMENT | IMATINIB CESSATION | DASATINIB | NILOTINIB | RELAPSE | IMPACT | ONCOLOGY | DISEASE | DEEP MOLECULAR RESPONSE | CML PATIENTS | Prognosis | Age Factors | Fusion Proteins, bcr-abl - isolation & purification | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Patient Selection | Young Adult | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Fusion Proteins, bcr-abl - blood | Adult | Remission Induction - methods | France | Neoplasm Recurrence, Local - blood | Watchful Waiting - standards | Patient Education as Topic | Medical Oncology - methods | Neoplasm Recurrence, Local - prevention & control | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Hematology - standards | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Consensus | Hematology - methods | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Medical Oncology - standards | Fusion Proteins, bcr-abl - metabolism | Tyrosine | Medical personnel | Myeloid leukemia | Physicians | Leukemia | Medical services | Chronic myeloid leukemia | Patients | Reintroduction | Biologists | Molecular chains | Training | Remission | Clinical medicine | Protein-tyrosine kinase | Monitoring | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article